Heartworms, macrocyclic lactones, and the specter of resistance to prevention in the United States

Particle and Fibre Toxicology

Dwight D Bowman¹ 

[1] Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, USA

关键词: Moxidectin;    Milbemycin oxime;    Selamectin;    Ivermectin;    Macrocyclic lactones;    Drug resistance;    Heartworm;    Dirofilaria immitis;   

Others  :  1231759
DOI  :  10.1186/1756-3305-5-138

 received in 2012-05-02, accepted in 2012-07-09,  发布年份 2012

【 摘 要 】

In order to provide a background to current concerns relative to the possible resistance of heartworms to macrocyclic lactones, this review summarizes various studies in which lack of efficacies (LOEs) have been observed in dogs on macrocyclic lactone preventives relative to the United States of America. Some of these studies have been published in the peer-reviewed literature, others have appeared in various reports to the Center for Veterinary Medicine (CVM) of the Food and Drug Administration (FDA) of the USA as New Animal Drug Application (NADA) summaries, and one appeared as a letter to US veterinarians. This review also discusses reports relating to the potential problem of heartworm resistance in microfilariae and third-stage larvae, as well as molecular markers associated with resistance to macrocyclic lactones within Dirofilaria immitis. As more work is being done in this area of great concern relative to the protection of dogs from infection using this class of preventives, it seems timely to summarize what is known about heartworms, their potential resistance to treatment, and the means of selecting for resistance genes in populations of this helminth in the laboratory and in the field.

【 授权许可】

   
2012 Bowman; licensee BioMed Central Ltd.

【 参考文献 】

• [1]NADA: 138–412 Heartgard-30®. http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm111205.htm?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=nada%20138-412&utm_content=1 webcite
• [2]NADA: 140–915 Interceptor®. http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/ webciteFOIADrugSummaries/ucm054857.htm?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=nada%20140-915&utm_content=5
• [3]NADA: 141–152 Revolution™. http://www.fda.gov/downloads/ webciteAnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm117201.pdf
• [4]NADA: 141–051 ProHeart™ for Dogs. http://www.fda.gov/AnimalVeterinary/ webciteProducts/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm116537.htm
• [5]NADA: 141–189 ProHeart®6. http://www.fda.gov/downloads/ webciteAnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm117588.pdf
• [6]NADA: 141–252 Advantage Multi® for Dogs. http://www.fda.gov/downloads/ webciteAnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM051438.pdf
• [7]Cupp EW, Bernardo MJ, Kiszewski AE, Collins RC, Taylor HR, Aziz MA, Greene BM: The effects of ivermectin on transmission of Onchocerca volvulus. Science 1986, 231:740-742.
• [8]Churcher TS, Pion SD, Osei-Atweneboana MY, Prichard RK, Awadzi K, Boussinesq M, Collins RC, Whitworth JA, Basanez MG: Identifying sub-optimal responses to ivermectin in the treatment of River Blindness. Proc Natl Acad Sci USA 2009, 106:16716-16721.
• [9]Prichard RK, Hall CA, Kelly JD, Martin ICA, Donald AD: The problem of anthelmintic resistance in nematodes. Aust Vet J 1980, 56:239-250.
• [10]Williamson SM, Storey B, Howell S, Harper KM, Kaplan RM, Wolstenholme AJ: Candidate anthelmintic resistance-associated gene expression and sequence polymorphisms in a triple-resistant field isolate of Haemonchus contortus. Mol Biochem Parasitol 2011, 180:99-105.
• [11]Reinemeyer CR, Prado JC, Nichols EC, Marchiondo AA: Efficacy of pyrantel pamoate against a macrocyclic lactone-resistant isolate of Parascaris equorum in horses. Vet Parasitol 2010, 171:111-115.
• [12]Traversa D, Samson-Himmelstjerna G, Demeler J, Milillo P, Schurmann S, Barnes H, Otranto D, Perrucci S, Regalbono AF, Beraldo P, Boeckh A, Cobb R: Anthelmintic resistance in cyathostomin populations from horse yards in Italy, United Kingdom and Germany. Parasit Vectors 2009, 2(Suppl 2):S2. BioMed Central Full Text
• [13]Kaminsky R, Bapst B, Stein PA, Strehlau GA, Allan BA, Hosking BC, Rolfe PF, Sager H: Differences in efficacy of monepantel, derquantel and abamectin against multi-resistant nematodes of sheep. Parasitol Res 2011, 109:19-23.
• [14]Wolstenholme AJ, Fairweather I, Prichard R, Samson-Himmelstjerna G, Sangster NC: Drug resistance in veterinary helminths. Trends Parasitol 2004, 20:469-476.
• [15]Kotze AC, le Jambre LF, O’Grady J: A modified larval migration assay for detection of resistance to macrocyclic lactones in Haemonchus contortus, and drug screening with Trichostrongylidae parasites. Vet Parasitol 2006, 137:294-305.
• [16]Atkins C: Current controversies and dilemmas in heartworm disease: defining the issues by close examination. https://www.aahanet.org/Education/ webciteWebConference.aspx?key=428166ce-8c29-462d-ad51-f7b9bd3b1350
• [17]Blagburn BL, Vaughan JL, Butler JM, Mount JD, Spencer JA, Carmichael J, Schenker R: Evaluation of susceptibility of heartworm (Dirofilaria immitis) biotypes to macrocyclic lactones using microfilariae-based single dose and dose-mortality regression assays [abstract]. In Proceedings of the AAVP 56th Annual Meeting. St. Louis, MO; 2011:110. 16–19 July 2011
• [18]Bourguinat C, Keller K, Bhan A, Peregrine A, Geary T, Prichard R: Macrocyclic lactone resistance in Dirofilaria immitis. Vet Parastiol 2011, 181:388-392.
• [19]Moorhead AD, Evans CC, Wolstenholm AJ, Storey BE, Blagburn BL, Vaughan JL, Schenker R, Carmichael J, Kaplan RM: In vitro bioassay for measuring anthelmintic susceptibility in Dirofilaria immitis [abstract]. In Proceedings of the AAVP 56th Annual Meeting. St. Louis, MO; 2011:109. 16–19 July 2011
• [20]Snyder DE, Wiseman S, Cruthers LR, Slone RL: Ivermectin and milbemycin oxime in experimental adult heartworm (Dirofilaria immitis) infection of dogs. J Vet Intern Med 2011, 25:61-64.
• [21]Snyder DE, Wiseman S, Bowman DD, McCall JW, Reinemeyer CR: Assessment of the effectiveness of a combination product of spinosad and milbemycin oxime on the prophylaxis of canine heartworm infection. Vet Parasitol 2011, 180:262-266.
• [22]NADA: 141–321 Trifexis. http://www.fda.gov/downloads/AnimalVeterinary/ webciteProducts/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM252248.pdf?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=nada trifexis&utm_content=1
• [23]Blagburn BL, Dillon AR, Arther RG, Butler JM, Newton JC: Comparative efficacy of four commercially available heartworm preventive products against the MP3 laboratory strain of Dirofilaria immitis. Vet Parasitol 2011, 176:189-194.
• [24]NADA: 141–333 Sentinel® Spectrum®. http://www.fda.gov/downloads/ webciteAnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM292003.pdf
• [25]Bourguinat C, Keller K, Prichard RK, Geary TG: Genetic polymorphism in Dirofilaria immitis. Vet Parasitol 2011, 176:368-373.
• [26]Bourguinat C, Keller K, Blagburn B, Schenker R, Geary TG, Prichard RK: Correlation between loss of efficacy of macrocyclic lactone heartworm anthelmintics and P-glycoprotein genotype. Vet Parasitol 2011, 176:374-381.
• [27]Bourguinat C, Keller K, Bhan A, Peregrine AS, Blagburn BL, Geary TG, Prichard RK: Macrocyclic lactone resistance in Dirofilaria immitis [abstract]. In Proceedings of the AAVP 56th Annual Meeting. St. Louis, MO; 2011:108. 16–19 July 2011
• [28]Belanger DH, Perkins SL, Rockwell RF: Inference of population structure and patterns of gene flow in canine heartworm (Dirofilaria immitis). J Parasitol 2011, 97:602-609.
• [29]McCall JW, Genchi C, Kramer L, Guerrero J, Dzimianski MT, Supakorndej P, Mansour AM, McCall SD, Supakorndej N, Grandi G, Carson B: Heartworm and Wolbachia: therapeutic implications. Vet Parasitol 2008, 158:204-14.